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1. Introduction
Bipolar disorder (BD) has been highly associated with disparate
cognitive deﬁcits including attention, psychomotor performance,
executive function, verbal ﬂuency, learning, memory and global
neurocognitive functioning [2,25–27]. Available evidence also
indicates that individuals with BD exhibit cognitive deﬁcits not only
during acute mood episodes but also during euthymia [26,27,41,43].
Moreover,arecentmeta-analysisreportedthateuthymicindividuals
generally had the same level of deﬁcits in memory and learning as an
actively symptomatic group [18]. Emerging evidence also indicates
that ﬁrst-degree relatives of probands with BD exhibit a similar
pattern of cognitive deﬁcits, providing the bases for hypothesizing
that cognitive abnormalities may represent an endophenotypic
marker of BD [4,43]. The pertinacity of cognitive deﬁcits in BD is
underscored by reports documenting an association between
cognitive deﬁcits and psychosocial functioning, workforce perfor-
mance and interpersonal adjustment [17,32,47].
Emerging evidence also indicates that obesity is associated with
reduced cognitive function in otherwise healthy individuals
[6,10,11,14,16,19,23,39]. The association between anthropometrics
and cognitive deﬁcits is detectable in individuals without obesity-
associated co-morbidities (e.g. type 2 diabetes mellitus and
hypertension) known to independently affect brain function
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Background. – Persistent impairment in cognitive function has been described in euthymic individuals
with bipolar disorder. Collective work indicates that obesity is associated with reduced cognitive
function in otherwise healthy individuals. This sub-group post-hoc analysis preliminarily explores and
examines the association between overweight/obesity and cognitive function in euthymic individuals
with bipolar disorder.
Methods. – Euthymic adults with DSM-IV-TR-deﬁned bipolar I or II disorder were enrolled. Subjects
included in this post-hoc analysis (n = 67) were divided into two groups (normal weight, body mass
index [BMI] of 18.5–24.9 kg/m2; overweight/obese, BMI  25.0 kg/m2). Demographic and clinical
information were obtained at screening. At baseline, study participants completed a comprehensive
cognitive battery to assess premorbid IQ, verbal learning and memory, attention and psychomotor
processing speed, executive function, general intellectual abilities, recollection and habit memory, as
well as self-perceptions of cognitive failures.
Results. – BMI was negatively correlated with attention and psychomotor processing speed as measured
by the Digit Symbol Substitution Test (P < 0.01). Overweight and obese bipolar individuals had a
signiﬁcantly lower score on the Verbal Fluency Test when compared to normal weight subjects
(P < 0.05). For all other measures of cognitive function, non-signiﬁcant trends suggesting a negative
association with BMI were observed, with the exception of measures of executive function (i.e. Trail
Making Test B) and recollection memory (i.e. process-dissociation task).
Conclusion. – Notwithstanding the post-hoc methodology and relatively small sample size, the results
of this study suggest a possible negative effect of overweight/obesity on cognitive function in euthymic
individuals with bipolar disorder. Taken together, these data provide the impetus for more rigorous
evaluation of the mediational role of overweight/obesity (and other medical co-morbidity) on cognitive
function in psychiatric populations.
 2011 Elsevier Masson SAS. All rights reserved.
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[19,20,39]. Most cognitive domains are reported to be adversely
affected by excess weight with replicated abnormalities in measures
of learning, memory and executive function [10]. A bi-directional
relationship between obesity and cognitive function is suggested by
studies reporting that individuals with impairment in executive
function are more likely to become overweight or obese, perhaps
related to disturbances in impulse control, self-monitoring, and
goal-directed behaviour [24]. It is further hypothesized that
cognitive abnormalities observed in overweight/obese individuals
are the expression of abnormalities in brain structure and function
[11,16,36].
It has been amply documented that individuals with BD are
differentially associated with overweight/obesity and abdominal
obesity, and excess weight adversely effects illness presentation,
course and outcome; however, to our knowledge, no published
study has primarily examined the association between over-
weight/obesity and cognitive function in adults with BD [15].
Herein, we preliminarily sought to determine whether such an
association exists in a well-characterized clinical cohort of
euthymic adults with BD I/II.
2. Methods
2.1. Overview
The data for the present analysis were obtained post-hoc from
screening and baseline assessments of euthymic individuals with
BD enrolled in a study that primarily aims to evaluate intranasal
insulin as a therapeutic intervention for cognitive function. For the
purpose of the analysis herein, participants were categorized into
normal weight and overweight/obese based on the established
criteria of body index mass (BMI) (normal weight, BMI of 18.5–
24.9 kg/m2; overweight/obese, BMI  25.0 kg/m2) [37].
2.2. Participants
Eligible participants for the principal study (age: 18–60) were
euthymic individuals with DSM-IV-TR-deﬁned BD I/II, conﬁrmed by
the Mini International Neuropsychiatric Interview (MINI) [1,42].
Euthymia, deﬁned as a score of less or equal to 3 on the 7-item
Hamilton Rating Scale for Depression (HAMD-7) and a score of less
or equal to 7 on the Young Mania Rating Scale (YMRS) was conﬁrmed
at the initial screening and 1 month later at baseline [33,43,48,49].
Subjects were permitted to maintain their medication regimens
such as conventional BD pharmacotherapy. No changes in medica-
tion were allowed during the study; medications were continued at
the time of cognitive assessment. Other inclusion criteria included
good physical health veriﬁed by a physical exam, provision of
informed consent and use of a medically accepted means of
contraception for females. Exclusion criteria included other
concurrent DSM-IV-deﬁned Axis-I diagnoses clinically signiﬁcant
untreated medical conditions (e.g. cardiovascular, neurological,
gastrointestinal, hematological, renal, hepatic, respiratory or endo-
crine illnesses), uncorrected hypo/hyperthyroidism (including
elevated thyroid stimulating hormone), the presence of diabetes
mellitus or hypo/hyperglycemia, history of neurological trauma
resulting in loss of consciousness, current pregnancy or breastfeed-
ing, or history of pregnancy in the last 12 months, electroconvulsive
therapy in the preceding 6 months, substance or alcohol abuse/
dependence in the last 3 months (meeting DSM-IV criteria) and BMI
greater or equal to 40 kg/m2 [1].
2.3. Procedures
Participants were largely recruited from referrals to the
outpatient Mood Disorders Psychopharmacology Unit, University
Health Network, University of Toronto and from media announce-
ments at local hospitals in the community. Their eligibility was
determined at the initial screening visit wherein their clinical state
(i.e. euthymia) and type of BD were conﬁrmed. A physical
examination was conducted to exclude those with major medical
conditions. After 2 weeks, eligible participants who provided
written informed consent and completed the initial assessment
were invited to the second screening during which their blood
pressure, pulse, height, weight, waist-to-hip ratio and BMI were
measured and their blood and urine samples were collected as part
of the evaluation. Demographic information and psychiatric
history were obtained by direct interview. Prior to the baseline
visit (which took place 4 weeks after the initial screening),
participants were asked to abstain from alcohol and smoking
cigarettes for 48 hours and 30 minutes, respectively, prior to the
blood sample collection. At baseline, euthymia was re-veriﬁed
prior to cognitive testing administered by trained research
personnel.
2.4. Cognitive measures
A battery of cognitive tests was administered to assess
estimated premorbid IQ (National Adult Reading Test [NART-R]
[38]), verbal learning and memory (California Verbal Learning
Test [CVLT-II] [12]), attention and psychomotor processing speed
(Trail Making Test A [TMT-A] [40] and Digit Symbol Substitution
Test [DSST] [46]), executive function (Trail Making Test B [TMT-B]
[40] and Verbal Fluency Test [3]), general intellectual abilities
(Shipley Abstraction [50]), recollection and habit memory
(Process-Dissociation Task [21]), and self-perceptions of cognitive
failures (Cognitive Failures Questionnaire [CFQ]) [5]. The cogni-
tive measures that were chosen in this study were based on
the primary hypothesis around the efﬁcacy of a cognitive
enhancing intervention. The cognitive battery was administered
by a trained research coordinator and took approximately 3 hours
to administer.
2.5. Statistical analyses
Statistical analyses were performed using SPSS version 16.0
(SPSS Inc., Chicago, IL). Since the variables presented normal
distribution, parametric tests were chosen. Demographic and
clinical characteristics of normal weight subjects and over-
weight/obese subjects were compared using Chi-square tests for
categorical variables and independent samples t-tests for
continuous variables. Correlations between BMI and measures
of cognitive performance were generated using Pearson’s
correlation tests. Performance on cognitive tests was compared
between the two groups using independent samples t-tests.
Statistical signiﬁcance was set at P < 0.05. In order to examine
the main effect of obesity on cognitive function, multivariate
analyses of covariance (MANCOVA’s) were conducted on test
performance in three different cognitive domains: verbal
learning and memory (measured by CVLT), attention and
psychomotor processing speed (measured by TMT-A and DSST),
and executive function (measured by TMT-B and Verbal Fluency
Test). The independent variable in each analysis included BMI
groups (normal vs. overweight/obese). Variables such as age and
the number of years of education counted from Grade 1 were
included in each model as covariates, which showed a signiﬁcant
association with dependent variables based on Pearson’s
correlation tests (P < 0.05). Binary logistic regression was
performed to assess the association between the dichotomous
dependent variable, BMI group, and predictor variables such as
age and the total number of correct responses on the Shipley
Abstraction subtest.
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3. Results
3.1. Sample characteristics
A total of 67 euthymic individuals with BD were included in the
analysis. 71.6% (n = 48) of the sample were overweight or obese.
Demographic and clinical characteristics are presented in Table 1
(the subjects removed did not differ in demographic or clinical
parameters from the 60 who were analyzed). There were no
signiﬁcant differences between normal and overweight/obese
groups in demography, except for sex wherein a higher proportion
of males were observed in the overweight/obese group than
expected. The two groups did not differ in clinical characteristics
including illness severity, age at the ﬁrst mood episode, the
number of lifetime mood episodes and the number of lifetime
hospitalizations for depression/mania. Moreover, current smoking
status and family history of mental illness did not differ
signiﬁcantly between the two groups (data not shown). All
subjects received conventional pharmacological treatment for
bipolar disorder. There were no signiﬁcant differences between
groups in the number or type of medications. Metabolic syndrome
components were exclusion criteria, and as such, there were no
differences in lipid or cholesterol proﬁles or markers of insulin
resistance. Also, the results remained unchanged after adjusting
for the effects of gender.
3.2. Correlation between BMI and measures of cognitive test
performance
BMI was signiﬁcantly and negatively correlated with scores on
the Digit Symbol Substitution Test (r = 0.320, P < 0.01). For most
of the analyses, a trend was observed in the hypothesized direction
wherein BMI was negatively correlated with various cognitive
measures.
3.3. Performance on cognitive tests by normal weight and overweight/
obese individuals with BD
Group mean performance and statistical comparisons for all
cognitive measures are summarized in Table 2. Subjects who were
overweight or obese had a signiﬁcantly lower score on the Verbal
Fluency Test compared to those who were normal weight
(P = 0.013). No signiﬁcant differences in performance on any other
cognitive measures were detected between the two groups.
3.4. Main effect of obesity on cognitive domains
Table 3 presents the main effect of obesity on cognitive
test performance. Results from MANCOVA analyses did not yield
any signiﬁcant main effect of obesity on cognitive function
domains (verbal learning and memory; attention and psychomo-
Table 1
Demographic and clinical characteristics of normal weight and overweight/obese euthymic individuals with bipolar disorder (BD).
Characteristic Normal weight (n = 19) Overweight/Obese weight (n = 48) P value
Sex (n, %) 0.008c
Female 14 (73.7) 18 (37.5)
Male 5 (26.3) 30 (62.5)
Age (mean, SD) 36.68 (10.36) 41.48 (9.90) 0.082
Ethnicity (n, %) 0.099
White 17 (89.5) 45 (93.8)
Black 1 (5.3) 0 (0)
Asian 0 (0) 3 (6.2)
Other 1 (5.3) 0 (0)
Number of years of education counted from Grade 1 (mean, SD)
(N: 16, O: 44)a
16.78 (2.61) 15.73 (3.00) 0.220
Type of BD (n, %) 0.776
BD I 16 (84.2) 39 (81.2)
BD II 3 (15.8) 9 (18.8)
Current medication (n)b
Antidepressants 11 20 0.230
Sleep medication 5 11 0.769
Anxiolytic 5 13 0.949
Anticonvulsants 15 38 0.984
Antipsychotic 11 30 0.727
Hormonal 5 8 0.368
Age at ﬁrst depressive episode (mean, SD)
(N = 18, O = 42)a
17.22 (5.91) 19.50 (9.78) 0.363
Age at ﬁrst manic episode (mean, SD)
(N = 17, O = 38)a
22.65 (6.10) 24.08 (10.72) 0.610
Number of lifetime depressive episodes (n, SD)
(N = 13, O = 28)a
6.23 (8.10) 10.32 (8.65) 0.159
Number of lifetime manic episodes (n, SD)
(N = 13, O = 28)a
6.46 (9.56) 7.00 (9.32) 0.865
Number of lifetime hospitalizations for depression (n, SD)
(N = 18, O = 42)a
0.72 (1.13) 1.19 (2.02) 0.360
Number of lifetime hospitalizations for mania (n, SD)
(N = 17, O = 43)a
0.71 (0.92) 0.81 (1.22) 0.743
a N: the number of subjects in normal weight group; O: the number of subjects in overweight/obese group.
b The majority of subjects received polypharmacy.
c Statistically signiﬁcant (P < 0.05).
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tor speed; and executive function) after accounting for the
confounders.
3.5. Predictor of obesity in euthymic individuals with BD
The sample size included in the regression analysis was 60
subjects (outliers and missing data excluded from the analysis)
(Table 4). Statistical analyses demonstrated that both age and the
score of the Shipley Abstraction subtest were not signiﬁcant
predictors of obesity in euthymic individuals with BD.
4. Discussion
To our knowledge, the analysis herein is the ﬁrst attempt to
assess whether overweight/obesity was associated with decrements
in cognitive function in euthymic individuals with BD. A high
proportion of the participants in this study were overweight or obese
(71.6%), as has been previously reported in bipolar populations
[31,34,35]. Possible factors contributing to obesity in BD include
lifestyle, medication exposure, neuroendocrine and neurotransmit-
ter dysfunctions, genetic predisposition and co-morbid conditions
such as binge-eating disorder [30,31,34,35]. Our data were unable to
determine whether obesity occurred prior to the onset of BD or as a
consequence of multi-episode/chronic illness and treatment.
In keeping with the view that increased body weight is
negatively correlated with cognitive function in non-psychiatric
samples, a trend was observed wherein BMI was inversely related
to cognitive test performance in euthymic individuals with BD
[19]. Moreover, in a separate study evaluating euthymic individu-
als, BMI was negatively correlated with the Global Assessment of
Table 2
Performance on cognitive measures by normal weight and overweight/obese euthymic individuals with BD.
Cognitive domains Normal weight (n = 19) Overweight/obese (n = 48) P value
Cognitive measures Mean (SD) Mean (SD)
Premorbid IQ 0.672
NART estimated full scale IQ 113.10 (9.23) 112.14 (8.08)
Verbal learning and memory
CVLT
Trials 1–5 free recall total correct 56.74 (11.48) 54.33 (12.05) 0.459
Short-delay free recall 11.16 (3.70) 10.56 (3.68) 0.553
Short-delay cued recall 12.32 (3.15) 11.86 (2.82) 0.543
Long-delay free recall 11.79 (3.54) 11.43 (3.46) 0.702
Long-delay cued recall 12.26 (3.14) 12.02 (3.10) 0.776
Attention and psychomotor processing speed
Trail Making Test A 32.12 (14.76) 32.94 (10.10) 0.798
(N = 18, O = 47)a
Digit Symbol Substitution Test 58.68 (11.80) 53.38 (11.26) 0.091
Executive function
Trail Making Test B 72.56 (26.89) 74.21 (35.42) 0.859
(N = 18, O = 47)a
Verbal Fluency Test 70.06 (19.50) 59.29 (13.87) 0.013b
General intellectual abilities
Shipley Abstraction subtest 14.11 (3.23) 13.90 (4.01) 0.840
Memory deﬁcits
HABCON
Recollection memory 0.36 (0.12) 0.34 (0.18) 0.778
(N = 14, O = 33)a
Habit memory 0.57 (0.11) 0.59 (0.11) 0.515
(N = 13, O = 33)a
Subjective measure
Cognitive Failures Questionnaire 54.74 (15.20) 57.46 (16.45) 0.535
a N: the number of subjects in normal weight group; O: the number of subjects in overweight/obese group.
b Statistically signiﬁcant (P < 0.05).
Table 3
Main effect of obesity on cognitive domain.
Cognitive domain (cognitive measures used) Number of subjects included
in the model (n)
df Pillai’s F P value
Verbal learning and memory (CVLT) 59 3, 53 0.399 0.754
Attention and psychomotor processing speed (TMT-A, DSST) 58 2, 53 0.548 0.582
Executive function (TMT-B, Verbal Fluency Test) 57 2, 52 1.991 0.393
Table 4
Binary logistic regression model of independent variables predicting obesity in subjects (n = 60).
Predictor Odds Ratio (OR) 95% CI for OR P value
Age 1.045 0.986–1.107 0.136
Total correct responses on Shipley Abstraction 1.022 0.871–1.199 0.788
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Functioning (GAF) [8] (the GAF has been positively correlated with
cognitive test performance in separate studies [27,28]). Based on
these previous ﬁndings, it may be inferred that BMI contributes to
decreased cognitive functioning in euthymic individuals with BD.
It is well established that impairments in executive function are
apparent in mixed populations of individuals with BD as well as
obese individuals without psychiatric disorders [7,10,16,19,
22,26,27,28,41,45]. It could be hypothesized that obesity and BD
are associated with common central nervous system structural and/
or functional changes in brain regions that subserve cognitive
functioning. For example, frontal cortical regions that mediate
executive function are hypometabolic in depressed individuals;
similarly, overweight/obese individuals manifest reduced metabolic
activity, as well as atrophy, in several cortical and subcortical
structures [13,41,44]. Moreover, the interrelationship between
obesity and mood disorders may be due to a pathophysiological
nexus that includes abnormalities in hypothalamus-pituitary-
adrenal axis function, inﬂammatory and metabolic systems,
disruption of brain circuitry, all of which are potential mediators
of cognitive function [9,10,28,43]. Further structural and functional
investigations, as well as the establishment of mechanisms
mediating cognitive deﬁcits in obesity and BD, are required before
a ﬁrm conclusion can be drawn.
Several methodological deﬁciencies limit inferences and
interpretations that can be made from these data. First, this study
was a sub-group post-hoc analysis that was not designed a priori to
address the association of cognition with overweight/obesity.
Secondly, the sample size was relatively small, increasing the
possibility of type II error. Thirdly, the sample was comprised of
individuals enrolled in a clinical trial at a university-based health
science centre, limiting generalizability to other patient popula-
tions. Fourthly, there was no attempt to ‘‘enrich’’ the sample for
individuals who have cognitive deﬁcits. As a result, considerable
heterogeneity in cognitive proﬁles was observed, which may have
also decreased the likelihood of detecting an association [22]
Fifthly, we did not have detailed information regarding the
duration of overweight/obesity. Studies in non-psychiatric popu-
lations indicate that the adverse effect of overweight/obesity may
be duration-dependent [19]. The inclusion of individuals with past
psychiatric co-morbidity was permitted, as was psychiatric
medicine, introducing additional confounds [28,29]. Finally, the
obese individuals in this study did not have co-morbid hyperten-
sion, diabetes mellitus or cardiovascular disease. It is not known if
our study results are representative of most other obese
individuals who have obesity-associated co-morbidity.
Taken together, this preliminary analysis is intended to be
hypothesis-generating rather than conﬁrming. It is our objective to
provide the impetus for more reﬁned evaluation of the mediation-
al/moderational role of overweight/obesity on cognitive function
in bipolar (and other psychiatric) populations. Hitherto, over-
weight/obesity and other medical co-morbidity pertinent to
cognitive function (e.g. diabetes mellitus) have not been system-
atically evaluated as variables possibly pertinent to cognitive
function in psychiatric populations. Future studies should also
consider whether weight loss strategies in BD offer a salutary effect
on cognitive function in addition to other beneﬁts on physical
health. Moreover, although we did not ﬁnd a difference between
bipolar I and bipolar II populations, a sufﬁciently powered study
should attempt to enroll both bipolar I and bipolar II populations,
as cognitive deﬁcits are prominent in both groups.
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